Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10434951 | 0.81 | MAPT (0.39) | MAPTGAATRPA1LMNAKDM4E | |
| SCHEMBL612799 | 0.81 | MAPT (0.39) | MAPTGAATRPA1LMNAKDM4E | |
| SCHEMBL5487950 | 0.75 | — | — | |
| SCHEMBL30373279 | 0.75 | — | — | |
| SCHEMBL10735763 | 0.75 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL10735757 | 0.75 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL8655845 | 0.73 | — | — | |
| SCHEMBL8655839 | 0.73 | — | — | |
| SCHEMBL9728983 | 0.73 | TRPA1 (0.31) | TRPA1 | |
| SCHEMBL4500203 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248877-A1 | Polycyclic diazodioxide-based Bcl-2 protein antagonists and use thereof | RICERCA BIOSCIENCES, LLC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004099162-A1 | POLYCYCLIC DIAZODIOXIDE-BASED BCL-2 PROTEIN ANTAGONIST | RICERCA BIOSCIENCES, LLC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248877-A1 | Polycyclic diazodioxide-based Bcl-2 protein antagonists and use thereof | BCL2L2, BCL2, BCL2L1 | MAPT 4829/4885GAA 4474/4885TRPA1 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.